Shanghai, China, August 4, 2026
AsymBio, the biologics-focused Contract Development and Manufacturing Organization (CDMO) and a subsidiary of Asymchem Group, has announced a capital injection totaling RMB 1.2397 billion (approximately US$184 million) to accelerate its long-term growth strategy and strengthen its global biologics manufacturing capabilities. The financing was led by Asymchem Group, alongside Hillhouse Qirui and other investors, reflecting strong confidence in AsymBio’s differentiated end-to-end biologics CDMO platform and its expanding role in supporting global pharmaceutical and biotechnology companies developing complex biologic therapies. Following completion of the transaction, Asymchem Group’s ownership stake will increase to 83.4965%, reinforcing its long-term commitment to expanding biologics manufacturing, research capabilities and commercial-scale production. The newly secured capital will be used to enhance GMP manufacturing capacity, accelerate technology platform development and support the growing demand for outsourced biologics manufacturing across global healthcare markets.
Strategic Investment Strengthens Global Biologics CDMO Platform
The latest financing marks a significant milestone in AsymBio’s growth strategy as demand continues to rise for specialized biopharmaceutical manufacturing services. Of the total investment, Asymchem Group will contribute approximately RMB 1.05 billion (US$156 million), while Hillhouse Qirui will invest approximately RMB 177 million (US$26 million), with additional participation from other investors. The investment reflects increasing confidence in AsymBio’s ability to deliver integrated one-stop CDMO solutions spanning early-stage research, process development, toxicology support, clinical manufacturing and commercial-scale production. As global pharmaceutical pipelines continue shifting toward increasingly complex biologic medicines, outsourcing has become a strategic priority for biotechnology innovators seeking flexible manufacturing partners with advanced technical capabilities. Company leadership believes the additional capital will strengthen operational scalability while positioning AsymBio to meet rapidly expanding client demand across multiple biologics development programs.
Growing Demand for Advanced Biologics Manufacturing
The investment comes at a time when the global biopharmaceutical industry is experiencing rapid growth in innovative therapeutic modalities, including antibody-drug conjugates (ADCs), novel drug conjugates (NDCs), bispecific antibodies, multispecific antibodies, and other advanced biologic therapies. As pharmaceutical companies continue expanding precision medicine pipelines, demand for specialized CDMO services capable of supporting complex biologics development and manufacturing has accelerated worldwide. AsymBio has continued investing heavily in research and development platforms, high-potency GMP manufacturing facilities, and high-containment production infrastructure capable of supporting increasingly sophisticated biologic products. The company generated approximately RMB 470 million (US$70 million) in revenue during 2025, while reporting first-quarter 2026 revenue exceeding RMB 140 million (US$21 million), demonstrating continued commercial momentum. The newly secured capital will further expand manufacturing capacity, improve operational efficiency and accelerate delivery of client programs while creating a stronger pathway toward long-term profitability.
Advertisement
Investment Supports Next Generation Biopharmaceutical Innovation
As a dedicated biologics CDMO, AsymBio continues expanding its capabilities beyond traditional monoclonal antibody manufacturing into next-generation therapeutic platforms, including ADCs, radio drug conjugates (RDCs), antibody-oligonucleotide conjugates (AOCs), antibody-protein conjugates (APCs), bispecific ADCs (BsADCs), dual-payload ADCs (dpADCs), fusion proteins, and recombinant proteins. Backed by Asymchem Group’s three decades of pharmaceutical manufacturing experience and global operational network, the company provides comprehensive development and manufacturing services supporting clients from early discovery through commercial production. The latest financing reinforces AsymBio’s commitment to expanding advanced biologics manufacturing infrastructure while supporting pharmaceutical innovators developing breakthrough therapies across oncology, immunology and other high-growth therapeutic areas. As biologic medicines continue transforming modern healthcare, the investment positions AsymBio to strengthen its international competitiveness, expand strategic partnerships and accelerate innovation throughout the global biopharmaceutical value chain.
Source: AsymBio press release
